Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.71 |
| ▸ | FAAH | O00519 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.52 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770695 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL8823490 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL15650882 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL25192010 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL17203900 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL25192009 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL17203784 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL5333001 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL19475767 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL19744696 | 1.00 | NOD1 (0.71) | NOD1FAAHMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378677-A1 | TREATMENT OF TOOTH DECAY USING A CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS | M. MUSTIX LTD (IL) | 2022-12-01 | — | — | US | claimed |
| CN-111978376-B | Pharmaceutical composition for preventing and/or treating coronavirus infection, and preparation method and application thereof | 江苏安泰生物技术有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-20210407677-A1 | FATTY ACID AND KREBS CYCLE METABOLOMIC MEASURES FOR TREATMENT OF HEAD INJURY | NORTHWESTERN UNIVERSITY (US) | 2021-12-30 | — | — | US | claimed |
| US-20210379010-A1 | COMPOSITIONS COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF BIOFILM AND CONDITIONS ASSOCIATED WITH MICROBIAL, FUNGAL, BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-12-09 | — | — | US | claimed |
| EP-3873449-A1 | COMPOSITIONS COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF BIOFILM AND CONDITIONS ASSOCIATED WITH MICROBIAL, FUNGAL, BACTERIAL INFECTIONS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2021-09-08 | — | — | EP | claimed |
| WO-2021084543-A1 | TREATMENT OF TOOTH DECAY USING A CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS | M. MUSTIX LTD (IL) | 2021-05-06 | — | — | WO | claimed |
| CN-111978376-A | Pharmaceutical composition for preventing and/or treating coronavirus infection, and preparation method and application thereof | 江苏安泰生物技术有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-111763246-A | Pharmaceutical composition for preventing and/or treating cervical cancer and preparation method and application thereof | 江苏安泰生物技术有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-111295181-A | Composition for external application to skin | 雷蒙德实验室博士 | 2020-06-16 | — | — | CN | claimed |
| US-9579335-B2 | Treatment of cystic diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-02-28 | — | — | US | claimed |
| US-20110044973-A1 | TREATMENT OF CYSTIC DISEASE WITH LYSOPHOSPHATIDIC ACID ANTAGONISTS | BLAZER-YOST BONNIE | 2011-02-24 | — | — | US | claimed |
| EP-1918287-A2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2008-05-07 | — | — | EP | claimed |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D | 2005-11-24 | — | — | US | claimed |
| JP-2004506604-A | — | — | 2004-03-04 | — | — | JP | claimed |
| EP-1263752-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | claimed |
| EP-1263752-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2002-12-11 | — | — | EP | claimed |
| WO-2001071022-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | NOD1 3695/4885FAAH 141/4885MEN1 4145/4885 |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | NOD1 3695/4885FAAH 141/4885MEN1 4145/4885 |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | NOD1 415/4885FAAH 329/4885MEN1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.